VivoSeq
Oncology

Desmoid Tumor

1

Pipeline Programs↗

7

Active Trials↗

2

Companies Involved↗

Desmoid Tumor is an early-stage landscape with 1 program across 2 companies. The most active players are SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, SpringWorks Therapeutics, Inc.. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

71/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

2 programs

ApprovedS

SpringWorks Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved1

Nirogacestat

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Analysis

Trial Status

16

clinical trials

Completed5 · 31%
Recruiting4 · 25%
Active, not recruiting3 · 19%
Unknown status2 · 13%
Terminated1 · 6%
Withdrawn1 · 6%

Clinical Trials

Trial Activity

16 trials

Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05879146·40 enrolled
Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting
Recruiting·UUniversity Hospital, Strasbourg, France·N/A·NCT06081400·150 enrolled
Study of Cryoablation and Nirogacestat for Desmoid Tumor
Recruiting·—·Phase 2·NCT05949099·28 enrolled
A Single-Arm, Open-Label Phase 4 Study of Nirogacestat in Adult Premenopausal Females With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Recruiting·SSpringWorks Therapeutics, Inc.·Approved·NCT07176689·50 enrolled
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Active, not recruiting·Children's Oncology Group·Phase 2·NCT04195399·35 enrolled
A Study of AL102 in Patients With Progressing Desmoid Tumors
Active, not recruiting·IImmunome, Inc.·Phase 2/3·NCT04871282·198 enrolled
A Single-arm, Open-label Phase 2 Study of Nirogacestat in Adult Japanese Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Active, not recruiting·SSpringWorks Therapeutics, Inc.·Phase 2·NCT07170644·20 enrolled
A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors
Completed·MMayo Clinic·Phase 1·NCT03627741·10 enrolled
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
Completed·Children's Oncology Group·Phase 2·NCT00068419·70 enrolled
Study to Evaluate Imatinib in Desmoid Tumors
Completed·HHeidelberg University·Phase 2·NCT01137916·39 enrolled
Vinblastine and Methotrexate in Treating Children With Desmoid Tumors
Completed·Children's Oncology Group·Phase 2·NCT00003019·28 enrolled
Toremifene in Treating Patients With Desmoid Tumors
Completed·—·Phase 2·NCT00002595·72 enrolled
18F-FES PET/CT in Imaging Patients With Desmoid Tumors
Terminated·VVanderbilt-Ingram Cancer Center·Phase 1·NCT02374931·3 enrolled
Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors
Withdrawn·—·Phase 2·NCT00978146
Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor
Unknown status·HHenan Cancer Hospital·N/A·NCT05490667·30 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)